Reata's CKD candidate improves kidney function in IgA nephropathy, diabetes cohorts

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from the IgA nephropathy and chronic kidney disease (CKD) associated with Type I diabetes cohorts of the open-label,

Read the full 242 word article

User Sign In